Adnexus is a leader in the discovery and development of Adnectins, a novel, proprietary type of targeted biologic. Adnectins are proteins that can be designed toward a broad range of targets. Given their simple structure, Adnectins are relatively straight forward to develop and produce. We believe this, and other important features of Adnectins, as well as our highly efficient proprietary processes for discovering and developing them (PROfusion™) creates an opportunity to rapidly generate compounds for further study in a broad range of disease types.
We create Adnectins using our proprietary protein engineering system called PROfusion. This technology enables us to easily engineer and test trillions of Adnectins against a target of interest to identify those Adnectins that we believe have the potential to offer the most desirable drug properties. PROfusion represents a significant improvement in discovery productivity by minimizing the time to identify high-quality candidates.
Click below to learn more about Adnectins and about PROfusion:
How do we do it?
Together, Adnectins and PROfusion enable design and development of innovative targeted therapeutics.